The invention relates to spirangien for use in the treatment or prevention of an Interleukin 6 (IL-6) or Interleukin 8 (IL-8) mediated disorder. The invention also provides a pharmaceutical formulation for use in the treatment or prevention of an IL-6 or IL-8 mediated disorder and a method of preventing or treating an IL-6 or IL-8 mediated disorder.